Neuroprotective effect of SGLT2 inhibitors.
Open accessThe DOI matches its Crossref record; 122 of the 124 references it cites were found in a registry or an index; 21 of the 97 sources its claims cite were checked for support.
Abstract
Patients with diabetes are at higher risk of cardiovascular diseases and cognitive impairment. SGLT2 inhibitors (Empagliflozin, Canagliflozin, Dapagliflozin, Ertugliflozin, Sotagliflozin) are newer hypoglycemic agents with many pleiotropic effects. In this review, we discuss their neuroprotective potential. SGLT2 inhibitors (SGLT2i) are lipid-soluble and reach the brain/serum ratio from 0.3 to 0.5. SGLT receptors are present in the central nervous system (CNS). Flozins are not fully SGLT2-selective and have an affinity for the SGLT1 receptor, which is associated with protection against ischemia/reperfusion brain damage. SGLT2i show an anti-inflammatory and anti-atherosclerotic effect, including reduction of proinflammatory cytokines, M2 macrophage polarization, JAK2/STAT1 and NLRP3 inflammasome inhibition, as well as cIMT regression. They also mitigate oxidative stress. SGLT2i improve endothelial function, prevent remodeling and exert a protective effect on the neurovascular unit, blood-brain barrier, pericytes, astrocytes, microglia, and oligodendrocytes. Flozins are also able to inhibit AChE, which contributes to cognitive improvement. Empagliflozin significantly increases the level of cerebral BDNF, which modulates neurotransmission and ensures growth, survival, and plasticity of neurons. Moreover, they may be able to restore the circadian rhythm of mTOR activation, which is quite a novel finding in the field of research on metabolic diseases and cognitive impairment. SGLT2i have a great potential to protect against atherosclerosis and cognitive impairment in patients with type 2 diabetes mellitus.
Overview
CoChat Summary
TL;DR
This narrative review summarizes proposed neuroprotective mechanisms of SGLT2 inhibitors in type 2 diabetes, atherosclerosis, and cognitive impairment, including anti-inflammatory, antioxidant, anti-atherosclerotic, AChE-inhibiting, BDNF-increasing, and mTOR-rhythm-restoring effects. It concludes that flozins have potential but that long-term clinical trials are needed to establish clinical relevance.
Key findings
- SGLT2 inhibitors are lipid-soluble and cross the blood-brain barrier, with brain/serum AUC ratios of 0.3 for canagliflozin and dapagliflozin and 0.5 for empagliflozin; SGLT1/SGLT2 are expressed in the CNS, and SGLT1 inhibition is linked to protection against ischemia/reperfusion brain damage.
- Anti-inflammatory and anti-atherosclerotic effects include reduced proinflammatory cytokines, M2 macrophage polarization, JAK2/STAT1 and NLRP3 inflammasome inhibition, and cIMT regression; empagliflozin reduced cIMT by 7.9% (p < 0.0001) after 3 months, and canagliflozin lowered IL-6 by 26.6% (p = 0.010) after 2 years.
- AChE inhibition may contribute to cognitive improvement: canagliflozin Ki = 0.12859 µM with estimated brain concentration ~3 µM, enough to inhibit AChE; empagliflozin Ki = 0.177 µM with brain concentration 0.5 µM, also enough; dapagliflozin Ki = 25.02 µM with brain concentration 0.3 µM, not enough.
- Empagliflozin significantly increased cerebral BDNF in db/db mice and improved cognition; in rat cerebral ischemia/reperfusion, empagliflozin dose-dependently reduced neuronal death, infarct size, and cognitive impairment via HIF-1α/VEGF signaling; SGLT2i may restore circadian mTOR activation and mimic fasting.
Methods
- Narrative review; no primary data collection or systematic search strategy is described.
- Evidence synthesized includes preclinical studies (murine/rat models, ex vivo, in silico) and selected clinical studies on SGLT2 inhibitors, atherosclerosis, inflammation, oxidative stress, mTOR signaling, cerebrovascular dysfunction, and Alzheimer’s disease pathology.
- Main analysis is a qualitative synthesis of mechanisms and reported outcomes, with one ongoing clinical trial noted: dapagliflozin in Alzheimer’s disease (NCT03801642).
Limitations
- The paper states that long-term clinical trials are necessary to establish whether the discussed mechanisms are clinically relevant, since atheroprotective and neuroprotective effects will not be immediate and require long-term SGLT2i intake.
- The paper notes that there is no available data on adverse CNS effects of flozins and that the exact mechanism of cardiovascular benefit has not been fully established.
- Evident from the text: this is a narrative review without systematic methods, and many key findings come from animal, ex vivo, or in silico studies, with limited human cognitive-outcome data.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
14 Valid · 1 Not valid · 67 Not checked · 11 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Canagliflozin, Dapagliflozin, Sotagliflozin significantly decrease the composed primary end-point, including cardiovascular mortality and other cardiovascular outcomes [10,11,12].”
§ Neuroprotective Effect of SGLT2 Inhibitors > 1. Introduction
What the sources say
- Supportedcites [10] Mahaffey, 2018, Canagliflozin for Primary and Secondary Prevention of Cardiovascular Events: Results from the CANVAS Program (Canagliflozin Cardiovascular Assessment Study), Circulation source
The Methods (Outcomes) define the composite endpoint as cardiovascular mortality, nonfatal myocardial infarction, or nonfatal stroke. The Results report that canagliflozin significantly reduced that endpoint versus placebo (P=0.02 for superiority). In this sentence with three citations, this source supports the canagliflozin portion; it is not offered as evidence for the other two drugs. (LLM, conf=0.93)
- Partly supportedcites [11] Wiviott, 2019, Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes, N. Engl. J. Med. sourceExperimental — accuracy not yet measured
The Cardiovascular and Renal Outcomes section reports that dapagliflozin significantly reduced the composite of cardiovascular death or hospitalization for heart failure. It also says the reduction was driven by fewer heart-failure hospitalizations, with no difference in cardiovascular death; MACE was not significantly reduced. This paper tests dapagliflozin, not the other two drugs named alongside it. Page numbers were not supplied in the passages. (LLM, conf=0.89)
- Supportedcites [12] Bhatt, 2021, Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure, N. Engl. J. Med. source
The Methods (p. 2) define the sotagliflozin trial’s composite primary endpoint as cardiovascular death, heart-failure hospitalization, and urgent heart-failure visits. The Efficacy End Points (p. 7) report a significantly lower rate for that composite with sotagliflozin than with placebo (hazard ratio 0.67; P<0.001). This source supports the sotagliflozin portion of the multi-citation sentence; it does not establish a significant reduction in cardiovascular death on its own. (LLM, conf=0.92)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“SGLT1 inhibitors are present in the pyramidal cells of the brain cortex, Purkinje cerebellum cells, hippocampus pyramidal, and granular cells [20].”
§ Neuroprotective Effect of SGLT2 Inhibitors > 2. Neurological Potential of SGLT2 Inhibitors
What the sources say
- Partly supportedcites [20] Poppe, 1997, Expression of the Na+-D-glucose cotransporter SGLT1 in neurons, J. Neurochem. sourceExperimental — accuracy not yet measured
The 'Expression of SGLT1 protein in brain' section and Fig. 7 report SGLT1 protein in cortical pyramidal cells, hippocampal pyramidal and granular cells, and cerebellar Purkinje cells. The citing sentence says 'SGLT1 inhibitors' are present; these passages identify the protein, not inhibitors. (LLM, conf=0.88)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“Among commonly used SGLT2 inhibitors, Canagliflozin has the greatest potential for inhibiting SGLT1 receptors.”
§ Neuroprotective Effect of SGLT2 Inhibitors > 2. Neurological Potential of SGLT2 Inhibitors
What the sources say
- Could not verifycites [27] Malhotra, 2015, Sodium glucose co-transporter inhibitors—A new class of old drugs, Int. J. Appl. Basic Med. Res. sourceExperimental — accuracy not yet measured
Our copy names canagliflozin only as 'the prototype drug among the newer agents' with its pharmacokinetics (PHARMACOKINETICS section), and it discusses SGLT-1/SGLT-2 selectivity in general terms (INTRODUCTION, HISTORICAL BACKGROUND, 'On fasting hypoglycemia'), but nowhere states that canagliflozin has the greatest SGLT-1 inhibitory potential among the SGLT2 inhibitors. The one place that could carry it — 'Table 1 New SGLT inhibitors and their status and selectivity' — appears in our copy only as a caption, with no table rows/indexed content, so the comparative selectivity data are not available to us. Searches for 'canagliflozin SGLT1 selectivity', 'selectivity ratio SGLT-1 versus SGLT-2 / IC50', 'Table 1 status and selectivity', and 'SGLT-1 inhibition adverse effects' returned no passage making or contradicting the claim. (LLM, conf=0.65)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“In humans, the serum level of IL-6 dropped by 26.6% (p = 0.010) after 2 years of canagliflozin treatment [35].”
§ Neuroprotective Effect of SGLT2 Inhibitors > 4. Inflammation
What the sources say
- Partly supportedcites [35] Heerspink, 2019, Canagliflozin reduces inflammation and fibrosis biomarkers: A potential mechanism of action for beneficial effects of SGLT2 inhibitors in diabetic kidney disease, Diabetologia sourceExperimental — accuracy not yet measured
The Abstract (Results) and Table 2 of our copy do carry the exact figure: canagliflozin 300 mg/day lowered IL-6 by 26.6% (95% CI −42.0, −7.2), p = 0.010, over 2 years (104 weeks) — but explicitly as a least-squares mean percentage DIFFERENCE VERSUS GLIMEPIRIDE and only at the 300 mg dose (100 mg gave −26.3%, p = 0.011), in people with type 2 diabetes and elevated albuminuria (CANTATA-D/SU subset, n = 296). The citing sentence recasts this between-group contrast as an absolute 'drop' of 26.6% from canagliflozin treatment alone, and drops both the comparator and the dose qualifiers. It also says 'serum', whereas the Methods (Biomarker measurement) state IL-6 was measured by Luminex assay on stored PLASMA samples. The magnitude, p value and 2-year duration are faithful; the attribution of the 26.6% as a within-treatment fall in serum is not supported. (LLM, conf=0.72)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“In previous studies, atherosclerotic lesions in intra- and extra-cranial arteries were associated with cognitive impairment and even dementia [2,66,67].”
§ Neuroprotective Effect of SGLT2 Inhibitors > 3. Atherosclerosis, Cognitive Impairment, and SGLT2i
What the sources say
- Not checked yetcites [2] Dearborn, 2017, Intracranial atherosclerosis and dementia The Atherosclerosis Risk in Communities (ARIC) Study, Am. Acad. Neurol.
- Supportedcites [66] Bos, 2015, Atherosclerotic calcification is related to a higher risk of dementia and cognitive decline, Alzheimer’s Dement. source
The Results section reports that after censoring for stroke, 'both extracranial and intracranial carotid artery calcification remained statistically significantly associated with dementia' (HR 1.32 and 1.34 per SD increase), and that larger calcification volumes were associated with cognitive decline in nondemented persons. The Abstract Conclusions and Discussion (generalized atherosclerosis 'is associated with dementia') state the same association for dementia and cognitive deterioration, matching the cited claim for both intra- and extra-cranial arteries. Minor wording differences (calcification as the atherosclerosis measure; 'cognitive decline' rather than 'cognitive impairment') do not alter the attributed content. (LLM, conf=0.88)
- Partly supportedcites [67] Wingo, 2020, Shared proteomic effects of cerebral atherosclerosis and Alzheimer’s disease on the human brain, Nat. Neurosci. sourceExperimental — accuracy not yet measured
The Abstract/Introduction of our copy supports the intracranial half of the claim: cerebral atherosclerosis is defined as plaques in 'the walls of large arteries in the brain' and is stated to be among the earliest changes associated with development of AD dementia, with ~three times higher risk for AD and nine times higher risk for vascular dementia (Abstract, p. 1). The METHODS confirm the paper's own atherosclerosis assessment covered only intracranial vessels — visual grading of the Circle of Willis (vertebral, basilar, posterior, middle and anterior cerebral arteries and proximal branches), not extracranial arteries (METHODS, ROS/MAP section). No passage in our copy addresses atherosclerotic lesions in extra-cranial arteries and cognition (searched: 'extracranial carotid atherosclerosis', 'carotid artery atherosclerosis systemic extracranial vessels'), so that part of the citing sentence is not supported by this source. (LLM, conf=0.72)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
42 more claims · 2 with their cited sources checked
Create a free account to see all 93 claims and to verify the 76 references still open.
- It may state two separate claims as one. 41
- Probably not a substantial claim. 6
- The quote only partly states this claim. 1
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Similarly, SGLT2is have demonstrated neuroinflammatory and antioxidative effects in addition to cardiovascular prevention.56”
From Cardioprotective Glucose-Lowering Agents and Dementia Risk: A Systematic Review and Meta-Analysis (2025) · cites this paper as [56]
Citations
Cites
1 retracted
Xue, L., Yuan, X., Zhang, S., & Zhao, X. (2021) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2021/9388562 · Cited by 20
RetractedEmpagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease
Ridker, P. M., Everett, B. M., Thuren, T., MacFadyen, J. G., Chang, W. H., Ballantyne, C., Fonseca, F., Nicolau, J., Koenig, W., Anker, S. D., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1707914 · Cited by 9,482 · cited 1×
“In the CANTOS study, inhibition of interleukin-1β with canakinumab significantly reduced cardiovascular risk independently of lipid levels [78].”
BackgroundDapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
Wiviott, S. D., Raz, I., Bonaca, M. P., Mosenzon, O., Kato, E. T., Cahn, A., Silverman, M. G., Zelniker, T. A., Kuder, J. F., Murphy, S. A., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1812389 · Cited by 6,382
Dapagliflozin in Patients with Chronic Kidney Disease
Heerspink, H. J. L., Stefánsson, B. V., Correa-Rotter, R., Chertow, G. M., Greene, T., Hou, F.-F., Mann, J. F. E., McMurray, J. J. V., Lindberg, M., Rossing, P., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2024816 · Cited by 5,618 · cited 1×
“The exact mechanism has not been fully established yet, and SGLT2 inhibitors show many additional beneficial effects which contribute to their wider use, even in non-diabetic patients [14].”
BackgroundReactive Oxygen Species in Inflammation and Tissue Injury
Mittal, M., Siddiqui, M. R., Tran, K., Reddy, S. P., & Malik, A. B. (2014) · Antioxidants & Redox Signaling · doi:10.1089/ars.2012.5149 · Cited by 4,897 · cited 4×
“The overproduction of ROS or decrease in the anti-oxidant defense results in oxidative stress, which is a significant contributor to vascular diseases, including atherosclerosis, as it causes endothelial dysfunction, promotes remodeling and further enhances inflammation [94].”
BackgroundInfluentialO'Leary, D. H., Polak, J. F., Kronmal, R. A., Manolio, T. A., Burke, G. L., & Wolfson, S. K. (1999) · New England Journal of Medicine · doi:10.1056/nejm199901073400103 · Cited by 4,685
The NLRP3 Inflammasome: an overview of mechanisms of activation and regulation
Kelley, N., Jeltema, D., Duan, Y., & He, Y. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20133328 · Cited by 3,539 · cited 1×
“It is a crucial element of the innate immune system activated not only by microbial infection or cellular damage but also by chronic inflammatory diseases, including atherosclerosis and Alzheimer’s disease [80].”
BackgroundEinarson, T. R., Acs, A., Ludwig, C., & Panton, U. H. (2018) · Cardiovascular Diabetology · doi:10.1186/s12933-018-0728-6 · Cited by 2,312 · cited 1×
“Type 2 diabetes mellitus (T2DM) is a chronic metabolic disease causing a variety of complications, including atherosclerosis which is associated with increased cardiovascular risk contributing to reduced life expectancy [1].”
BackgroundSotagliflozin in patients with diabetes and recent worsening heart failure
Bhatt, D. L., Szarek, M., Steg, P. G., Cannon, C. P., Leiter, L. A., McGuire, D. K., Lewis, J. B., Riddle, M. C., Voors, A. A., Metra, M., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2030183 · Cited by 1,868 · cited 1×
“It is even called a “dual SGLT1/SGLT2 inhibitor”, however, it is the newest Flozin, and it is not yet used in diabetic patients on a large scale [12].”
Background
Research works printed but not linked: 1
- Esterline, R., Oscarsson, J., and Burns, J. (2020). International Review of Neurobiology, Elsevier Inc.. [1st ed.].
Cited by
Items 201–300 of 326
Osman, S. T., Elzahhar, P. A., Hakim, M. A., Sanni, A., Hamdy, N. A., Purba, W. T., Bhuiyan, M. M. A. A., Onigbinde, S. B., Sandilya, V., Hassan, N. W., et al. (2026) · British Journal of Pharmacology · doi:10.1111/bph.70331 · Cited by 2
“Furthermore, SGLT2i administration has been linked to enhanced production of brain-derived neurotrophic factor (BDNF), a key regulator of synaptogenesis and synaptic plasticity that plays a crucial role in cognitive processes such as learning and memory (Miranda et al., 2019; Pawlos et al., 2021).”
Zhang, L., Zhang, L., Wen, H., Wu, S., Yu, H., Zhao, L., & Li, G. Y. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1754543 · Cited by 5
“Subsequent studies show that SGLT2 inhibitors enhance endothelial function, inhibit pathological remodeling, and protect the BRB, BBB, and neurovascular unit (98).”
Kumari, K., Bai, A., Geeta, F. N. U., Wadhwani, N., Kumar, R., Kumar, A., Kumari, R., Bai, L., Muskan, F., Kashish, F. N. U., et al. (2026) · Endocrinology Diabetes & Metabolism · doi:10.1002/edm2.70174 · Cited by 2
Liu, X., Pang, H., Pan, X., Fan, S., Deng, Y., Yu, M., Xie, X., & Pan, Y. (2026) · BMC Cardiovascular Disorders · doi:10.1186/s12872-026-05745-5 · Cited by 2
SGLT2 Inhibitors in Alzheimer’s Disease: Biochemical Insights and Therapeutic Potential
Mazzeo, P., Vietri, M., Tecce, N., Delizia, A., Remondelli, V., Ciaglia, T., Dio, A. D., Corletti, L., Pizzuti, C. G., Pepe, G., et al. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27115051 · Cited by 2
Puranik, K., Ranpise, N. S., Khot, S. V., & Negi, P. (2026) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2026.115161 · Cited by 2
Sodium-Glucose Cotransporter 2 Inhibitors and Dementia Risk in Patients With Psychiatric Disorders
Liebers, D. T., He, T., Betensky, R. A., Zheng, C., Swinnerton, K. N., Sean, J., Huhmann, L., Brophy, M. T., Do, N., Gilsanz, P., et al. (2026) · JAMA Network Open · doi:10.1001/jamanetworkopen.2026.19985 · Cited by 2
Liu, S., Liu, X., Hu, J., Chen, H., Yang, S., Feng, J., & Sui, Y. (2026) · Journal of Translational Medicine · doi:10.1186/s12967-026-08574-4 · Cited by 2
“The proposed inflammasome-independent and non-immune functions of NLRP3 remain among the most controversial issues in the field and require rigorous validation [16, 55].”
Shokr, M. M., Abu-Elsaoud, A. M., & Raish, S. M. A. (2026) · Molecular Neurobiology · doi:10.1007/s12035-026-06065-7 · Cited by 3
Protective Effect of SGLT2 Inhibitor on D-Galactose-Induced Senescence in Mice and Its Mechanism
Ma, Z., Xu, M., Jin, K., Zhu, G., & Chen, X. (2023) · Journal of Biosciences and Medicines · doi:10.4236/jbm.2023.115021 · Cited by 2
Yánez, T. R., Jiménez, L. C. V., Daza-Arnedo, R., guette, C. M. R., Montejo-Hernández, J. D., Márquez, V. O., & Rico-Fontalvo, J. E. (2023) · Revista de la Sociedad Ecuatoriana de Nefrología Diálisis y Trasplante · doi:10.56867/59 · Cited by 2
Chen, T., Lee, H., Chan, Y., Chuang, C., Li, P., Yeh, Y., Su, H., & See, L. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15804 · Cited by 2
Petrovska, L., Kostitska, I. O., Petrovskyy, T., & Petrovskyy, R. (2025) · INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine) · doi:10.22141/2224-0721.20.8.2024.1470 · Cited by 2
Fernandes, J. V., Ramos, J. M., & Holanda, M. M. D. A. (2025) · Minerva Medica · doi:10.23736/s0026-4806.25.09695-8 · Cited by 3
Enache, I. I., Manea, M. M., Tuță, S., & Sîrbu, C. A. (2025) · Clinical Neurology and Neurosurgery · doi:10.1016/j.clineuro.2025.108981 · Cited by 2
Comparative evaluation of SGLT-2i and GLP-1RA neuroprotective properties in type 2 diabetic patients
Murasheva, A. V., Каронова, Т. Л., Станиславовна, Ф. О., Тимкина, Н. В., Fedotova, A. D., Grineva, E. N., & Shlyakhto, E. V. (2025) · Diabetes Mellitus · doi:10.14341/dm13255 · Cited by 2
use of SGLT2 inhibitors in the treatment of cognitive disorders
Lato, M., Iberszer, K., Litwiniuk, M., Zaniuk, M., HURKAŁA, K., ANTONIK, D., Denys, B., Góra, K., Zimnicki, P., & Zdziennicki, W. (2023) · Journal of Education Health and Sport · doi:10.12775/jehs.2023.25.01.003 · Cited by 2
SGLT2 inhibitors and their possible use in prevention and treatment of neurological diseases
Sobczyk, M., Żuraw, D., Oleksa, P., Jasiński, K., Porzak, M., & Dacka, M. (2024) · Prospects in Pharmaceutical Sciences · doi:10.56782/pps.176 · Cited by 2
“Grzbietowo-przyśrodkowa część rdzenia przedłużonego – jądro pasma samotnego [4,19,24] 3.”
Drug Therapy for Unexplained Dyspnea in Post–COVID-19 Fatigue Syndrome: Empagliflozin and Sildenafil
Manu, P. (2022) · American Journal of Therapeutics · doi:10.1097/mjt.0000000000001483 · Cited by 2
Ishikawa, J., & Harada, K. (2023) · JACC Asia · doi:10.1016/j.jacasi.2022.10.009 · Cited by 2
Sodium-Glucose Co-transporter Type-2 Inhibitors’ Effect on Quality of Life in Older Adult Population
Tutan, D., Kaya, A. E., & Kayaalp, M. (2023) · Cureus · doi:10.7759/cureus.47005 · Cited by 1
“Previous studies in older adult patients have demonstrated cardiorenal protective effects and beneficial effects on cognitive function through antioxidant, antiatherogenic, and direct neuroprotective effects [8,9].”
Dong, Y., Long, B., Tian, Z., Huang, J., & Wei, Y. (2024) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2024.110733 · Cited by 1
Yadav, R., Mani, R. J., Kumar, A. H. S., Ahmad, S., & Katare, D. P. (2024) · Biomedical & Pharmacology Journal · doi:10.13005/bpj/2990 · Cited by 2
Re-purposing SGLT-2 inhibitors for diabetic striatopathy
Chatterjee, S., Ghosh, R., Dubey, S., & Holt, R. I. G. (2024) · Primary care diabetes · doi:10.1016/j.pcd.2024.10.001 · Cited by 1
Mechanism for the association between diabetes or anti‐diabetic medications and incident dementia
Araki, A. (2025) · Geriatrics and gerontology international/Geriatrics & gerontology international · doi:10.1111/ggi.70066 · Cited by 1
“8 SGLT2 inhibitors suppress cognitive dysfunction in type 2 diabetic mice by reducing oxidative stress and increasing the level of brain-derived neurotrophic factor (BDNF).”
Protective effects of empagliflozin against NMDA-induced excitotoxicity in the rat retina
Ota, M., Morita, A., Kashihara, T., & Nakahara, T. (2025) · Neuroscience Letters · doi:10.1016/j.neulet.2025.138315 · Cited by 1
Mehanny, M., Sabry, N. C., Ihab, H., Ashraf, Z., MOSTAFA, M. D. N. E. S. M., Hamed, R., Wael, N., Abdelkarim, F., Younis, A., Ismail, A., et al. (2025) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2025.107313 · Cited by 4
Li, Z., Niu, H., Chen, J., & Li, W. (2025) · Brain Circulation · doi:10.4103/bc.bc_3_25 · Cited by 3
“[87] Receptor for advanced glycation end products inhibitors They can improve microvascular function by improving oxidative stress and inflammation.”
Huang, Y., Yu, X., & Li, C. (2025) · CNS Drugs · doi:10.1007/s40263-025-01230-3 · Cited by 1
“Owing to their lipophilicity, SGLT2i cross the BBB [64] and directly target brain SGLT2 proteins, effectively preventing brain edema caused by excessive glucose and sodium absorption.”
Abolfazli, S., Atkin, S. L., Jamialahmadi, T., & Sahebkar, A. (2025) · Glycoconjugate Journal · doi:10.1007/s10719-025-10197-8 · Cited by 2
Unraveling the Genetic Links: The Impacts of Antidiabetic Drugs on Stroke Risk
Chen, J., Wang, Y., Li, L., & Xu, J. (2025) · Reviews in Cardiovascular Medicine · doi:10.31083/rcm40051 · Cited by 1
“Moreover, numerous studies have suggested that SGLT2 inhibitors may confer a neuroprotective effect against critical pathological alterations associated with CSVD [41].”
Severini, G., Armentaro, G., Cassano, V., Condoleo, V., Pastura, C. A., Panza, A., Fuoco, C., Miceli, S., Fiorentino, T. V., Perticone, M., et al. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1664988 · Cited by 1
“In addition, some authors have proposed a pleiotropic effect, suggesting bene fi ts that extend to the neuroprotective role (Pawlos et al., 2021).”
Effectiveness of antidiabetic drugs to prevent dementia in people with diabetes
Palui, R., & Ray, S. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-33355-2.00010-4 · Cited by 1
Agrawal, N. K., & Phirke, Y. H. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-33355-2.00037-2 · Cited by 1
Borikar, S. P., Bokade, B. A., Jain, S. P., Zore, P. S., Tapre, D. N., Paliwal, N. P., & Shelke, S. P. (2025) · Next research. · doi:10.1016/j.nexres.2025.101210 · Cited by 4
Ma, J., Liu, X., Qin, Y., Qu, Y., Liu, Q., & Li, J. (2025) · Experimental Eye Research · doi:10.1016/j.exer.2025.110803 · Cited by 1
Another pleiotropic effect of SGLT2 inhibitors: Is it a new frontier in thyroid function regulation?
Szklarz, M., Wołos-Kłosowicz, K., Szulc, J., Górny, J. M., Modzelewski, R., & Matuszewski, W. (2026) · Thyroid Research · doi:10.1186/s13044-025-00282-3 · Cited by 1
Cheng, H., Jing, Y., Xu, C., Chen, M., Su, H., Yang, X., & Zhang, L. (2026) · Drug Design Development and Therapy · doi:10.2147/dddt.s567851 · Cited by 2
Dong, M., Xu, Z., Zhou, L., & Wen, S. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1689167 · Cited by 1
“Pawlos et al. indicated that SGLT-2i can achieve a brain/serum ratio of 0.5 (44), which indirectly supports our fi ndings regarding the distribution of DAPA-Cy3 in the PVN, NTS, arcuate nucleus (ARC), and cerebral cortex.”
InfluentialAbdel‐Aal, R. A., Meligy, F. Y., Kamel, G., & Ashry, I. E.-S. M. (2026) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2026.178581 · Cited by 1
Chao, Y., Jiao, J., Zhang, B., Sun, J., Tong, X., Yang, H., Wu, T., Zhang, Z., & Bi, Y. (2026) · Journal of Endocrinological Investigation · doi:10.1007/s40618-025-02775-2 · Cited by 1
Wang, X., Zhao, Z., Sun, L., Gao, C., Wang, L., Mei, D., Hao, C., Zhao, S., Yan, X., Liu, J., et al. (2026) · Brain Communications · doi:10.1093/braincomms/fcag083 · Cited by 1
“15,17,42 This study investigates the therapeutic potential of ertugliflozin to attenuate autism spectrum disorder-like features in BTBR mice while concurrently elucidating its underlying mechanisms of action.”
InfluentialAnti-diabetic medications to fight Parkinson's disease and dementia with Lewy bodies: a pilot study
Chmiela, T., Dulski, J., Heckman, M. G., Fang, Z. J., Wszołek, Z. K., & Wilson, J. R. (2026) · Frontiers in Neurology · doi:10.3389/fneur.2026.1825229 · Cited by 1
Lénárt, I., Horváth, O., Molnár, K., Bereczki, C., Monostori, P. B., Klivènyi, P., & Galla, Z. (2026) · Scientific Reports · doi:10.1038/s41598-026-55891-1 · Cited by 1
“Emerging evidence indicates that EMPA may have neuroprotective effects in neurodegenerative disease models 27–29 .”
Gamal, N. K., Fakhry, R., Hatem, Y., Rashed, E., Marzouk, R., Bukr, A. K. M., Safwat, K., Mamdouh, M., Abdelfatah, A., Atallah, A., et al. (2026) · Inflammopharmacology · doi:10.1007/s10787-026-02292-5 · Cited by 1
“In addition to decreasing body weight and increasing peripheral insulin sensitivity, this class also enhances brain mitochondrial function, lowers neurodegeneration, and modulates the gut microbiota (George et al. 2026; Pawlos et al. 2021 ).”
Grasso, M., Maggio, V., Caraci, F., & Rizzo, M. (2026) · Advances in Therapy · doi:10.1007/s12325-026-03760-8 · Cited by 1
Acierno, C., Cavallo, M., D’Ardes, D., Boccatonda, A., Nilo, D., & Caturano, A. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27188063 · Cited by 1
“Neuroprotective effects of SGLT2 inhibitors have also been reported, plausibly reflecting reduction in systemic and possibly central inflammatory tone [82]. signalling; and gut-barrier/microbiota-derived signalling.”
Sodium-glucose cotransporter-2 inhibitors: A treatment option for recurrent vasovagal syndrome?
Sanoudou, D., Mantzoros, C. S., & Hill, M. A. (2022) · Metabolism · doi:10.1016/j.metabol.2022.155309 · Cited by 1
Psoriasiform lesions as a side effect of SGLT-2 therapy
Gałązka, J. K., Domagalski, Ł., Homa, P. K., & Hoffman, Z. (2023) · Quality in Sport · doi:10.12775/qs.2023.09.01.004 · Cited by 1
From a Glycocentric Approach to Prevention of Multi-Organ Damage in Type 2 Diabetes
Grover‐Páez, F., Gómez, A. M., Suárez, A., & Echauri, A. M. (2023) · IntechOpen eBooks · doi:10.5772/intechopen.1002363 · Cited by 2
Zerebrale Mikroangiopathie: Fortschritte im Verständnis der Pathophysiologie
Henneicke, S., Meuth, S. G., & Schreiber, S. (2023) · Fortschritte der Neurologie · Psychiatrie · doi:10.1055/a-2190-8957 · Cited by 1
“Experimentell verbessern sie die En - dothelfunktion und haben protektive Effekte auf den pathologi - schen Umbau der neurovaskuläre Einheit und der BHS [50].”
Molaei, E., Molaei, A., Dashti‐Khavidaki, S., Nasiri‐Toosi, M., Abbasi, M.-R., & Jafarian, A. (2024) · Medical Hypotheses · doi:10.1016/j.mehy.2024.111417 · Cited by 1
Parlițeanu, O.-A., Nemeș, R.-M., Bălteanu, M. A., Radu, D., & Gherlan, G. S. (2025) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2025.12862 · Cited by 1
“Studies have shown that the use of SGLT‑2 inhibitors reduced cerebral ischemia and also improved cardiovascular outcomes following the modelling of a stroke in animals (26).”
Li, Y., Xu, M., Tang, Y., Zhao, X., & Chen, M. (2026) · Current Diabetes Reviews · doi:10.2174/0115733998444053260211052025 · Cited by 1
Цивунін, В. В., Штриголь, С. Ю., Настека, М. В., & Нехороша, Є. O. (2022) · Pharmacology and Drug Toxicology · doi:10.33250/16.03.147
Станиславовна, Ф. О., Симаненкова, А. В., Тимкина, Н. В., Александровна, Т. П., Gagiev, А. Z., & Каронова, Т. Л. (2023) · Consilium Medicum · doi:10.26442/20751753.2023.4.202277
“Уменьшение гиперактивации mTOR нивелирует указанные выше патологические изменения, уменьшает выраженность эндотелиальной дисфункции и воспаления [20].”
Pulla-Urgiles, D. A., Jiménez, A. A. E., & Arteaga, M. P. J. (2023) · LATAM Revista Latinoamericana de Ciencias Sociales y Humanidades · doi:10.56712/latam.v4i2.1043
Shestakova, M. V., Galstyan, G. R., Grineva, E. N., Zilov, A. V., Demidova, T. Y., Mkrtumyan, A. M., Petunina, N. A., Ruyatkina, L. A., Sukhareva, O. Y., Суплотова, Л. А., et al. (2023) · Diabetes Mellitus · doi:10.14341/dm13086
Shin, Y., Park, J., Kim, J. H., Ah, Y., & Choi, H. D. (2023) · Journal of Korean Society of Health-System Pharmacists · doi:10.32429/jkshp.2023.40.4.003
Inhibidores del Cotransportador Sodio-Glucosa Tipo 2 en la Diabetes Mellitus Tipo 2 en Adultos
Iñiguez, L. K. E., Espinoza, E. V. V., & Fernández, R. E. A. (2025) · Ciencia Latina Revista Científica Multidisciplinar · doi:10.37811/cl_rcm.v9i1.15879
Association of TAB2 gene polymorphism with endometrial cancer susceptibility and clinical analysis
Long, S., & Wang, Y. (2025) · Journal of Turkish Society of Obstetric and Gynecology · doi:10.4274/tjod.galenos.2025.24983
Keep your guard up: blood–brain barrier protection by empagliflozin after acute ischaemic stroke
Hochrainer, K., Hansen, A., & García‐Bonilla, L. (2025) · Cardiovascular Research · doi:10.1093/cvr/cvaf049 · Cited by 1
Huang, X., Yin, B., Hu, Q., Zheng, Q., Chen, B., Wang, J., Ji, X., & Su, K. (2025) · Molecular Neurobiology · doi:10.1007/s12035-025-04987-2
“Additionally, SGLT2 inhibitors (SGLT2i) have neuroprotective effects against key pathological changes caused by CSVD [13].”
Sodium-glucose cotransporter-1 inhibition and depression: A Mendelian randomization study
Fan, G., Zuo, H., Shi, X., & Liu, B. (2025) · SAGE Open Medicine · doi:10.1177/20503121251352618
The Effect of Dapagliflozin on Absence Epilepsy in WAG/Rij Rats
Aygün, H. (2025) · Archives of Epilepsy · doi:10.4274/archepilepsy.2025.25179
Elfaki, E. M., Al-Kuraishy, H. M., Al-Gareeb, A. I., Albuhadily, A. K., Eliwa, D., Alexiou, A. T., Papadakis, M., & Batiha, G. E. (2025) · Neuroscience · doi:10.1016/j.neuroscience.2025.10.045
Malakapogu, P., Shyma, Z., Shetty, S., Bagchi, D., & Miraj, S. S. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-33355-2.00032-3
Oxidative stress in brain accelerates the onset of neurodegeneration in hyperglycemic individuals
Rios-Dávila, A. A., Pérez‐Capistran, T., Rodríguez-Vera, D., Mera-Jiménez, E., Rodríguez, M. H., & Soriano-Ursua, M. A. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-33355-2.00004-9
Direct consequences of diabetes on the nervous system: structural and molecular pathological changes
Mendes, O. R. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-33355-2.00003-7
Engineering the Gut Microbiome for Metabolic, Reproductive, and Cognitive Health
Maissy, E. S. (2024) · eScholarship (California Digital Library)
Sarabhai, T., Zingel, D. R. M. R., Bohlken, J., & Kostev, P. D. R. M. H. K. (2025) · Monitor Versorgungsforschung · doi:10.24945/mvf.03.25.1866-0533.2781
Chu, C.-H., Hsu, Y., Lee, C., Lin, L.-Y., Chuang, W.-L., Lin, H.-J., Lin, C., Cho, D., & Chang, K.-H. (2025) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-025-02026-7
“Third, neuroprotective effects of SGLT2i on the central nervous system have been documented in preclinical models, including increased expression of brain-derived neurotrophic factor (BDNF) and reduced amyloid accumulation [37–39].”
Антонова, К. В., Панина, А. А., Лагода, О. В., Schukina, E. P., & Weber, S. A. (2025) · FOCUS Endocrinology · doi:10.62751/2713-0177-2025-6-4-07
Celestino, M. J., Pereira, P. E. M., Soares, A. G., Mello, R. S., Takeuchi, A. B., Januário, P. R., Ribeiro, C. L., & Ribeiro, E. L. (2026) · Revista Contemporânea · doi:10.56083/rcv6n1-028
Hawkins, A., & McCoy, R. G. (2026) · Diabetes Obesity and Cardiometabolic CARE · doi:10.2337/doc25-0020
POTENTIAL EFFECTS OF SGLT-2 INHIBITORS ON PARKINSON DISEASE
Baskın, V. (2026) · TOGÜ Sağlık Bilimleri Dergisi · doi:10.52369/togusagbilderg.1652318
Ünal, İ. (2023) · Dspace Repository (Marmara Üniversitesi)
Kim, M. H., Gil, J. Y., Min, K. H., Kim, J. H., Park, J. H., Park, S., Han, J. M., & Lee, K. E. (2026) · Diabetes and Vascular Disease Research · doi:10.1177/14791641261431777
The Potential Role of Antidiabetic Agents in Bipolar Disorder
Landivar, E., Gabriel, F. C., Daolio, L. D., & Lafer, B. (2026) · Current Treatment Options in Psychiatry · doi:10.1007/s40501-026-00375-2
“Pawlos et al. (2021) [62] reported improved mitochondrial function, higher BDNF, and reduced neuronal oxidative stress.”
The Use of RNA-Based Therapeutics in the Treatment of Metabolic Diseases
童, 璐. (2026) · Hans Journal of Biomedicine · doi:10.12677/hjbm.2026.162022
Kiyak‐Kirmaci, H., Hazar‐Yavuz, A. N., Polat, E. B., DOĞAN, M. O., Tok, F., Çilingir-Kaya, Ö. T., & ELCIOGLU, H. K. (2026) · Behavioural Brain Research · doi:10.1016/j.bbr.2026.116158
Solis, D. J., & Cascante, C. V. (2023) · Investigative News in Education (Universidad de Costa Rica)
Gomes, K. D. S., de Souza, P. P., Pieretti, N. P. L., Almeida, E. A., Bernardo, R., Filho, W. Q. M., Fedatto, P. F., & Gomez, A. P. B. (2026) · Scripta Scientia · doi:10.66201/ss.v1.10
What’s new in heart failure? February 2026
Lee, M. M. Y., Tomasoni, D., & Aimo, A. (2026) · European Journal of Heart Failure · doi:10.1093/ejhf/xuag107
Guo, X., Yang, T., Fang, Y., & Chen, J. (2026) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s599108 · Cited by 1
“33 In vitro studies reveal that empagli-flozin mitigates dendritic and spine alterations induced by hydrogen peroxide in primary neurons and inhibits neuronal ferroptosis induced by oxygen–glucose deprivation/reoxygenation.”
Talyshinskii, A., Gauhar, V., Yuen, S. K. K., Güven, S., Tokas, T., Tsaturyan, A., Enikeev, D. V., & Somani, B. K. (2026) · Asian journal of urology · doi:10.1016/j.ajur.2025.11.004
“Considering the incomplete selectivity of flozins and the partial blockade of SGLT1, their use is beneficial in brain diseases [45,46].”
Saleem, T., Rasool, M. F., Saeed, H., & Alqahtani, F. (2026) · Drug Metabolism Reviews · doi:10.1080/03602532.2026.2668704
“…are lipid-soluble and cross the blood-brain barrier, reaching the brain-to-serum ratio of the areas under the curves up to 0.5 for empagliflozin (Pawlos et al. 2021; Dai et al. 2025). it is associated with several adverse effects, most notably symptomatic hypotension, genital fungal infections,…”
InfluentialChen, Y., Jiang, Z.-H., Chen, J., & Wu, V. (2026) · GeroScience · doi:10.1007/s11357-026-02300-0
Borikar, S. P., Chavan, M. S., Jain, S. P., Lokwani, D. K., & Tapre, D. N. (2026) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-026-05352-3 · Cited by 1
“On day 42, after the completion of behavioral tests, all animals were anesthetized with chloral hydrate (400 mg/kg) and sacrificed (Pawlos et al. 2021; Danao et al. 2021).”
Erectile Dysfunction Evaluation in Diabetic Patients Using SGLT-2 Inhibitors
İNCAMAN, D. (2026) · European Journal of Medical and Health Sciences · doi:10.24018/ejmed.2026.8.2.70236
“Emerging evidence suggests that SGLT-2 inhibitors exert broad biological effects extending beyond glucose lowering, encompassing reno-protective, cardioprotective, and neuroprotective properties [18], [19].”
Li, J., Dai, W., Alavi, R., Carreño, J. E., Arakaki, X., Pahlevan, N. M., & Kloner, R. A. (2026) · Journal of the American Heart Association · doi:10.1161/jaha.125.047087
“40 However, the heart expresses minimal SGLT2 receptors, which means that the effects of empagliflozin on the heart are primarily off-target (eg, sodium–hydrogen exchanger 1 inhibition).”
Sőth, S. T., Bagosi, Z., Farkas, A., Gasztonyi, B., & Bujtor, Z. (2026) · Magyar Belorvosi Archívum · doi:10.59063/mba.2026.79.2.2
Ngiam, J. N., Loy, E. X., Koh, M. C. Y., Chiew, C. J., Li, R. J., Lim, S. C., Tai, E. S., Bee, Y. M., Chow, W. L., Lye, D. C., et al. (2026) · Infectious Diseases and Therapy · doi:10.1007/s40121-026-01362-z
“Further possible explanations for the neuroprotective effects of SGLT2i may include enhancing ketone metabolism, improving cerebral blood flow, and modulating oxidative stress [45–49].”
Yazi, S., Özen, B., Buldu, B., Yalçın, E., Karakose, O., Cakmak, O., Somunkiran, S., Yananlı, H. R., Sehirli, U. S., & Kirazlı, Ö. (2026) · Brain Structure and Function · doi:10.1007/s00429-026-03142-4
“Moreover, it decreased AChE activity (Stanciu et al. 2023 (Elariny et al. 2024).”
InfluentialGhosal, S., Roy, M., & Roy, N. (2026) · International Journal of Drug Delivery Technology · doi:10.25258/ijddt.16.56s.57
Dapagliflozin pretreatment attenuates focal cerebral ischemia-reperfusion injury in rats
Beytur, A., Korkmaz, E., Tanbek, K., & Tekin, S. (2026) · Molecular Biology Reports · doi:10.1007/s11033-026-12191-1
“Although SGLT1 and SGLT2 are best known for mediating sodium-driven glucose reabsorption in the kidney [7 ], they are also expressed in the central nervous system [8].”
Venkei, Z. G., & Savelieff, M. G. (2026) · Exploration of neuroscience · doi:10.37349/en.2026.1006139
Okamoto, T., Sasaki, H., Morisaki, Y., Yokoyama, S., Saito, Y., & Nakagawa, I. (2026) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x261468880
Pharmacologic strategies in prediabetic neuropathy
Fuentes‐Mendoza, J. M., Concepción‐Zavaleta, M. J., Garcia-Ramirez, Suyón-Ríos, N. A., Urteaga, L. A. C., Basurto-Ayala, A., & Paz‐Ibarra, J. (2026) · Current Medical Research and Opinion · doi:10.1080/03007995.2026.2706312
“Their effects on inflammatory and vascular processes may be linked to changes in oxidative stress, although direct effects on peripheral nerves have not been demonstrated 64,65 .”
Metadata
- Authors
- Pawlos, A., Broncel, M., Woźniak, E., & Gorzelak-Pabiś, P.
- Affiliations
- Medical University of Lodz (PL)
- Laboratory of Tissue Immunopharmacology, Department of Internal Diseases and Clinical Pharmacology, Medical University of Lodz, Kniaziewicza 1/5, 91-347 Lodz, Poland
- Corresponding author
- Broncel, Marlena
- Venue
- Molecules
- Publisher
- MDPI AG
- Published
- 2021-11-28
- Volume
- 26
- Issue
- 23
- Pages
- 7213
- ISSN
- 1420-3049 (ISSN-L)
- PMC
- PMC8659196
- OpenAlex
- W3214770882
- Semantic Scholar
- d4fddd52e53127993c142ff6d31526f815eb1c00
- Cited by
- 304
- References
- 124
- Citations by year
- 2026: 66 · 2025: 92 · 2024: 71 · 2023: 50 · 2022: 25
- FWCI
- 4.26
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Molecules (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Life Sciences › Neuroscience › Neurology › Neuroprotection in Cerebral Ischemia
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Life Sciences › Neuroscience › Neurology › Neurological Disease Mechanisms and Treatments
- Keywords
- SGLT2 inhibitors, neuroprotection, type 2 diabetes, cognitive impairment, cardiovascular disease, anti-inflammatory activity, NLRP3 inflammasome, cerebral blood flow, neurovascular unit, blood-brain barrier, acetylcholinesterase inhibition, brain-derived neurotrophic factor, atherosclerosis
- MeSH terms
- Sodium-Glucose Transporter 2 Inhibitors, Animals, Brain, Diabetes Mellitus, Type 2, Humans, Hypoglycemic Agents, Neuroprotective Agents, Atherosclerosis, Sodium-Glucose Transporter 2, Cognitive Dysfunction
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-04, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-04 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol and qwen3.8-omni-flash).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.